The company said it received notice on January 1 from the FDA’s Center for Veterinary Medicine that the funding will support its ongoing effectiveness study of Canalevia-CA1
The report also revealed that 87% of physicians agreed that FEE recommendations would help to improve the speed of recovery
Under the deal, Hims & Hers will offer patients access to FDA-approved versions of Ozempic and Wegovy at the same self-pay prices available through other telehealth platforms
The company announced positive topline data from the Phase II ZUPREME-1 trial
BRAFTOVI in combination with cetuximab and mFOLFOX6 had previously received accelerated approval in December 2024 based on objective response rate (ORR) results
The trial targeted a patient population with high BMI and extensive skin involvement, averaging over 39 kg/m²
Wegovy is now offered in six weekly doses in the EU: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg, and the newly approved 7.2 mg dose
The PRIOH-1 study met its primary endpoint, delivering statistically significant and clinically meaningful improvements in lesion healing
Venglustat, a glucosylceramide synthase inhibitor (GCSi), works by reducing the abnormal buildup of sugar-and-fat molecules in cells and organs
Subscribe To Our Newsletter & Stay Updated
